Vol 36(2020) N 3 p. 3-15; DOI 10.21519/0234-2758-2020-36-3-3-15
E.V. Petersen1*, D.A. Chudakova2, E.Yu. Skorova1, I.V. Reshetov1,3

Practical Applications of 3D Cell Culture Biotechnologies for Translational Oncology and Personalized Therapy

1Moscow Institute of Physics and Technology, Dolgoprudny Moscow Oblast, 141701 Russia
2School of Biological Sciences, University of Auckland, Auckland, New Zealand, 1010
3LM. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Moscow, 119991 Russia

Received - 12.12.2019; Accepted - 15.05.2019


The creation of in vitro three-dimensional cellular model systems (in vitro 3D cultures) is a fast-growing leading-edge segment of the biotechnological industry. We have examined in this work the key 80 articles published after 2008, and focused on applications of in vitro 3D culture in translational oncology. We described a broad range of 3D culture systems, including models with and without extracellular matrix (ECM). 3D culture models based on decellularized ECM were discussed in more detail. The role of ECM in pathogeneis of malignant neoplasms, in particular, in the phenomenon of the tumor resistance to chemotherapy, was evaluated. 2D and 3D culture systems were compared, and natural and synthetic ECM were described, as well as the model creation based on 3D bioprinting. Particular attention was paid to in vitro models of various cancers, including those at the metastatic stage, based on 3D cell cultures, which maximally mimic the in vivo tumor behavior. The prospects of the practical application of 3D cell culture models in preclinical drag screening and in personalized therapy were discussed. We also presented our data on in vitro 2D and 3D culturing of human cells on various substrates.

3D cellular models, 3D bioprinting, biotechnology, extracellular matrix, cancer, translational medicine, personalized medicine, drag development, in vitro, ex vivo, oncology

The authors are grateful to Dr. E. Shabalina for providing part of the experimental data and to OKA-Biotech Company for the samples of recombinant Funding-The work was supported by a Grant from the Russian Science Foundation (no. 18-15-00391). doi: 10.21519/0234-2758-2020-36-3-3-15